Contineum Therapeutics News and Activities

Contineum Therapeutics is a company listed under the stock ticker CTNM (US).

View the org chart displaying its 35 main executives

Most searched biographies at Contineum Therapeutics

• Carmine Stengone, Director, President and Chief Executive Officer
• Evert Schimmelpennink, Director
• Olivia Ware, Director

Popular executive movements at Contineum Therapeutics

• Brian Wiens has joined the company as Vice President, Head of Biometrics  (posted on May 19 2026).
• James Swaney has joined the company as Vice President, Translational Sciences  (posted on March 30 2026).

Create your alert
to follow the executive moves at Contineum Therapeutics.

Contineum Therapeutics has 2,424 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• The new name of EG 427 is Cyllene Therapeutics. (posted on July 10 2026).
• Opthea will change its company name to Ceryvyn Therapeutics on Jul 9, 2026. (posted on July 9 2026).
• Tissium has just announced a $60 Million fundraising (posted on July 8 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Contineum Therapeutics

• Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry | Contineum Therapeutics
• Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 | Contineum Therapeutics
• Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference | Contineum Therapeutics
• Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain | Contineum Therapeutics
• Contineum Therapeutics to Attend Upcoming Investor Conferences | Contineum Therapeutics
• News Releases | Contineum Therapeutics
• News Releases | Contineum Therapeutics
• Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | Contineum Therapeutics
• Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences | Contineum Therapeutics
• Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights | Contineum Therapeutics
• View more press releases Close

Social media about Contineum Therapeutics

• Contineum Therapeutics on Wikipedia, Google News & Yahoo Finance
• Contineum Therapeutics on LinkedIn, X (Twitter) & YouTube